Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting. (April 2014)

• Record Type: Journal Article
• Authors: Meissner, Brian; Trivedi, Digisha; You, Min; Rosenblatt, Lisa
• Is Part Of: Journal of medical economics. Volume 17:Number 4(2014)
• Page Start: 259
• Page End: 265
• Publication Date: 2014-04
• Subjects: Medical care -- Cost control -- Periodicals; Medical economics -- Periodicals; 362.10941
• DOI: 10.3111/13696998.2014.893241
• Languages: English
• ISSNs: 1369-6998

Abstract

<abstract> <title>Abstract</title> <sec id="ss1"> <title>Objectives:</title> <p>This study examined total healthcare costs and rates of patients with rheumatoid arthritis (RA) who switch biologic disease-modifying anti-rheumatic drug (bDMARD) therapy in a real world setting.</p> </sec> <sec id="ss2"> <title>Methods:</title> <p>A retrospective longitudinal analysis was conducted in patients with RA using IMS PharMetrics Plus database from 1/1/2004 to 3/31/2010. The first-line cohort included patients newly initiated on abatacept or the tumor necrosis factor-alpha inhibitors (anti-TNFs) adalimumab, etanercept, or infliximab, with 12 months of continuous follow-up. The second-line cohort included patients initiating a bDMARD with evidence of a different bDMARD within the previous 2 years and with 12 months of continuous follow-up. Switching was defined as a different bDMARD claim within a 200% gap in days supply from the previous bDMARD claim. Non-switchers stayed on their bDMARD in the follow-up period. Monthly total healthcare costs for switchers and non-switchers and rates of bDMARD switching were examined. Switch rates for each bDMARD were also compared.</p> </sec> <sec id="ss3"> <title>Results:</title> <p>First-line switchers had significantly higher monthly total healthcare costs after the switch than non-switchers ($3759 vs $2343; <italic>p</italic> < 0.05), as did second-line switchers ($3956 vs $2616; <italic>p</italic> < 0.05). First-line abatacept (2.1%) had significantly lower rates of switching compared to adalimumab (9.5%), etanercept (9.0%), and infliximab (5.5%). Second-line abatacept (8.0%) had significantly lower rates of switching compared to adalimumab (16.7%), etanercept (14.4%), and infliximab (14.3%).</p> </sec> <sec id="ss4"> <title>Limitations:</title> <p>There are no clinical data available in this database and, therefore, this study did not examine the clinical drivers of healthcare costs and switch rates.</p> </sec> <sec id="ss5"> <title>Conclusions:</title> <p>Monthly total healthcare costs were higher for bDMARD switchers following the switch compared to non-switchers. Patients on abatacept switched less frequently than patients on anti-TNFs. This study highlights the need to identify patients who are likely to switch in order to ensure they receive the appropriate therapy which may improve outcomes and decrease healthcare costs.</p> </sec> </abstract>